34results about How to "Significant effect in treating rheumatoid arthritis" patented technology

The invention relates to the field of medicaments, and in particular relates to polypeptide capable of inhibiting a tumor necrosis factor-alpha and preventing and treating rheumatoid arthritis. The polypeptide is modified by polyethylene glycol and the sequence of the polypeptide, namely mPEG-SC10k-Pro-Thr-Met-Ser-Trp, is a brand-new sequence. The polypeptide disclosed by the invention has the beneficial effects of being capable of treating rheumatoid arthritis and having potential value on development of new medicaments.

The invention discloses application of polypeptides in preparation of medicament for treating or preventing rheumatoid arthritis, belongs to the field of medicament and particularly relates to polypeptides with integrin affinity and binding capacity. The polypeptides comprise a polypeptide I, a polypeptide II and a polypeptide III which can be used for preventing or treating rheumatoid arthritis; the polypeptide I has the following amino acid sequence: Ala-Cys-Asp-Cys-Arg-Gly-Asp-Cys-Phe-Cys-Gly-Gly-Gly-Gly-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro, wherein the amino acid sequence comprises two pairs of disulfide bonds, and the disulfide bonds have the pairing mode of 1-4 and 2-3; the polypeptide II has the following amino acid sequence: Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Gly-Gly-Gly-Gly-Arg-Gly-Asp; and the polypeptide III has the following amino acid sequence: mPEG-SC20k-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Gly-Gly-Gly-Gly-Arg-Gly-Asp. The polypeptides can be used for treating the rheumatoid arthritis.

The invention provides a nuclear factor-KB polypeptide inhibitor 5 and an application thereof, relates to the field of medicines, and particularly relates to a polypeptide which can inhibit the nuclear factor-KB and can be used for preventing and treating chronic infectious arthritis. The sequence is a brand-new sequence SHGGLPCQNS. The nuclear factor-KB polypeptide inhibitor 5 has the beneficial effects that the nuclear factor-KB polypeptide inhibitor 5 can be used for treating the chronic infectious arthritis and has a potential new medicine development value.

The invention discloses a nuclear factor-KB polypeptide inhibitor 3 and application thereof, relates to the field of medicines and in particular relates to a polypeptide with effects of inhibiting nuclear factor-KB and preventing and treating rheumatoid arthritis. The sequence of TRILAQHRLYINNSGGE is a brand new sequence. The nuclear factor-KB polypeptide inhibitor 3 has the beneficial effects that the nuclear factor-KB polypeptide inhibitor 3 can be used for treating the rheumatoid arthritis and has the potential new drug development value.

The invention relates to tumor necrosis factor-alpha polypeptide inhibitors and application thereof. The invention relates to the field of medicine, and particularly relates to polypeptides capable of inhibiting matrix metal proteinase-2 and tumor necrosis factor liberase and relieving damage of acute inflammation response on organisms. The sequence of the polypeptide is Pro-Thr-Thr-Asn-Arg which is a brand-new sequence. The inhibitors can inhibit the activities of the matrix metal proteinase-2 and tumor necrosis factor liberase in vitro on the 1 micromole level, and increase the survival rate of endotoxin shock mice in an in-vivo test, thereby having potential new drug development value.

The invention provides a nuclear factor-KB polypeptide inhibitor 4 and an application thereof, relates to the field of medicines, and in particular relates to a polypeptide capable of inhibiting a nuclear factor-KB and preventing and treating chronic infectious arthritis. The polypeptide has a brand new sequence of GILHGGVTRKDVVP. The polypeptide has the beneficial effect of being capable of treating the chronic infectious arthritis, thereby having a potential novel medicine development value.

The invention discloses an application of a blocker with integrin affinity and bonding capability and MMPs (matrix metalloproteinases) inhibiting capability, and belongs to the field of medicines. The application comprises a polypeptide I (Arg-Gly-Asp-Gly-Gly-Gly-Gly-Pro-(D-Pyr)-(D-Cys)-Bip-Arg-Gly-Glu) and a polypeptide II (Pro-(D-Pyr)-(D-Cys)-Bip-Arg-Gly-Glu-Gly-Gly-Gly-Gly-Arg-Gly-Asp), wherein the polypeptide I is modified with an integrin ligand sequence (Arg-Gly-Asp-Gly-Gly-Gly-Gly); two types of blood vessel inhibiting polypeptides with integrin affinity and bonding capability are formed. The application has the advantages that because of the targeting property of an RGD (arginine-glycin-aspartate) sequence, the polypeptides can be targeted to the new blood vessel endothelium of the RA (rheumatoid arthritis) pannus forming process, the forming of MMPs (matrix metalloproteinases) and the new blood vessel can be inhibited, and the effect of preventing or treating the blood vessel and inflammatory diseases are realized; the polypeptides can be applied to the treatment of the blood vessel and inflammatory diseases, such as arthritis, inflammation, tumors, and eye diseases.

The invention relates to the field of drugs, and particularly relates to a compound capable of inhibiting proteasomes and preventing and treating rheumatoid arthritis. The compound has the molecular structure of benzyl-4-(benzyloxy)-dimethoxy benzoate. The compound has the beneficial effects that the compound can be used for treating rheumatoid arthritis, and has potential new drug development value.

The invention relates to the field of medicines, and concretely relates to a polypeptide capable of inhibiting interleukin-6 and preventing and treating rheumatoid arthritis. The sequence of the polypeptide is TPSPTSKAILMEKL which is a brand new sequence. The polypeptide can be used for treating the rheumatoid arthritis and has potential new drug exploitation values.